Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Emergency Medicine
Volume 2018, Article ID 3452691, 3 pages
https://doi.org/10.1155/2018/3452691
Case Report

Acute Intoxication following Dimethyltryptamine Ingestion

1Salina Regional Health Center, 400 S Santa Fe Avenue, Salina, KS 67401, USA
2University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
3Owensboro Health Regional Hospital, 1201 Pleasant Valley Road, Owensboro, KY 42303, USA

Correspondence should be addressed to Matthew H. Bilhimer; moc.liamg@remihlibhm

Received 7 July 2017; Revised 15 January 2018; Accepted 16 January 2018; Published 27 February 2018

Academic Editor: Aristomenis K. Exadaktylos

Copyright © 2018 Matthew H. Bilhimer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Araújo, F. Carvalho, M. D. L. Bastos, P. Guedes de Pinho, and M. Carvalho, “The hallucinogenic world of tryptamines: an updated review,” Archives of Toxicology, vol. 89, no. 8, pp. 1151–1173, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. A. R. Winstock, S. Kaar, and R. Borschmann, “Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample,” Journal of Psychopharmacology, vol. 28, no. 1, pp. 49–54, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. C. W. Heise and D. E. Brooks, “Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015,” Journal of Medical Toxicology, 2016. View at Google Scholar
  4. R. Harris and L. Gurel, “A study of ayahuasca use in North America,” Journal of Psychoactive Drugs, vol. 44, no. 3, pp. 209–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Domínguez-Clavé, J. Soler, M. Elices et al., “Ayahuasca: Pharmacology, neuroscience and therapeutic potential,” Brain Research Bulletin, vol. 126, pp. 89–101, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Cunningham, “Hallucinogenic plants of abuse,” EMA - Emergency Medicine Australasia, vol. 20, no. 2, pp. 167–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Riba, A. Rodríguez-Fornells, G. Urbano et al., “Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers,” Psychopharmacology, vol. 154, no. 1, pp. 85–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Riba and M. J. Barbanoj, “Bringing ayahuasca to the clinical research laboratory,” Journal of Psychoactive Drugs, vol. 37, no. 2, pp. 219–230, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Warren, “Fatal nicotine intoxication resulting from the ingestion of, ayahuasca,” Journal of Analytical Toxicology, pp. 28–287, 2004. View at Google Scholar
  10. J. Sklerov, B. Levine, K. A. Moore, T. King, and D. Fowler, “A fatal intoxication following the ingestion of 5-methoxy-N,N- dimethyltryptamine in an ayahuasca preparation,” Journal of Analytical Toxicology, vol. 29, no. 8, pp. 838–841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Guimarães dos Santos, “Safety and Side Effects of Ayahuasca in Humans-An Overview Focusing on Developmental Toxicology,” Journal of Psychoactive Drugs, vol. 45, no. 1, pp. 68–78, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. A. S. Lima and L. F. Tófoli, “An epidemiological surveillance system by the UDV: mental health recommendations concerning the religious use of hoasca,” in The Internationalization of Ayahuasca, B. C. Labate and H. Jungaberle, Eds., pp. 185–199, Lit Verlag, Zurich/Berlin, 2011. View at Google Scholar
  13. J. C. Callaway and C. S. Grob, “Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions,” Journal of Psychoactive Drugs, vol. 30, no. 4, pp. 367–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. “Joint Appendix,” O Centro Espirita Beneficiente Uniao Do Vegetal et al. v. John Ashcroft, no. CV02-2323, on Writ of Certiorari to the US Court of Appeals for the 10th Circuit, New Mexico, 2002.
  15. R. S. Gable, “Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids,” Addiction, vol. 102, no. 1, pp. 24–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. G. Szmulewicz, M. P. Valerio, and J. M. Smith, “Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report,” International Journal of Bipolar Disorders, vol. 3, no. 1, 2015. View at Publisher · View at Google Scholar
  17. R. G. dos Santos, F. L. Osório, J. A. S. Crippa, and J. E. C. Hallak, “Antidepressive and anxiolytic effects of ayahuasca: A systematic literature review of animal and human studies,” Revista Brasileira de Psiquiatria, vol. 38, no. 1, pp. 65–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. R. G. dos Santos, F. L. Osório, J. A. Crippa, J. Riba, A. W. Zuardi, and J. E. Hallak, “Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years,” Therapeutic Advances in Psychopharmacology, vol. 6, no. 3, pp. 193–213, 2016. View at Publisher · View at Google Scholar
  19. M. Taj, “Canadian man kills Brit in psychedelic ceremony in Peru's Amazon,” http://www.reuters.com/article/us-peru-crime-drugs-idUSKBN0U101520151218 Reuters UK, 2015.